The Chain: Protein Engineering Podcast

Episode: 88 - Janice Reichert on the Evolution of Antibody Therapeutics

How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of

Episode: 87 - Jack Elands on How Novel ADC Payloads Could Improve Cancer Care

July 14, 2026 | Most ADCs today lean on the same Topo-1 payloads—and resistance is catching up. Jack Elands, Ph.D., founder and CEO of Adcytherix, speaks with host Rakesh

Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D

At this year’s PEGS Boston, industry experts gathered on a panel to explore how AI and machine learning are deployed in biologics R&D today. Moderated by Peter M. Tessier

Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating

May 12, 2026 | When it comes to drug discovery, either you find a rare, clean target and everything clicks, or you spend a decade chasing biology that refuses to cooperat

Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design

How is BindCraft, the automated pipeline for de novo protein binder design, changing the protein design industry? Martin Pacesa, assistant professor of pharmacology at th

Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement

T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan The

Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?

During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years

Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research

How has immunotherapy evolved in the last decade? In this episode of The Chain, Laszlo Radvanyi, professor of immunology at the University of Toronto, discusses his years

Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity

December 13, 2025 | What is next for immunogenicity? In this episode of The Chain, Vibha Jawa, chief scientific officer at EpiVax, provides her thoughts and insights on B

Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs

November 11, 2025 | What is the next modality to focus on in the next 10 years? For Bahija Jallal, CEO of Immunocore, it would be T-cell engagers. In this episode of The

Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability

As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with

Episode: 77 - Derek Lowe on AI and the US Biotech Ecosystem

September 16, 2025 | With the rise of AI and automation, what is the core human skill in drug discovery that is and will be valuable in the future? Derek Lowe, director o

Alexey Lugovskoy Shares Decades of Experience in Starting Out and Founding Companies

August 12, 2025 | Diagonal Therapeutics founder and CEO Alexey Lugovskoy discusses the key lessons learned over his illustrious career, starting from his childhood in the

Episode: 75 - Are Licensing Fees Required or Gatekeeping?

July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wi

Episode: 74 - Keith Flaherty, President-Elect of AACR, on Public and Private Collabs, AI Optimism, and More

June 10, 2025 | In this bonus episode of The Chain, Daniel Chen, MD, PhD, founder and CEO of Synthetic Design Lab, returns for the Science Commune segment and speaks with

Episode: 73 - PANEL DISCUSSION: Near-Term Challenges for AI/ML in Biotherapeutic R&D

June 10, 2025 | This episode of The Chain features a panel discussion from May’s PEGS Boston. Moderated by Peter Tessier, Albert M. Mattocks professor of Pharmaceutical S

Episode: 72 - Pamela Barney on HR Lessons to Meet the Needs of Biotech

In this episode of The Chain, host Tariq Ghayur, PhD, Tariq Ghayur Consulting, LLC, talks with Pamela Barney, former associate director of HR, AbbVie, about her career wi

PEGS Young Scientist Keynote Jessica Stark on the Role of Glycans in Cancer Research

In this episode of The Chain, host Brandon DeKosky, associate professor, speaks with MIT colleague Jessica Stark, Underwood-Prescott career development professor, about g

Episode: 70 - Views on Machine Learning and AI in the Antibody and Protein Engineering Space

March 11, 2025 | In this episode of The Chain, host Andrew Buchanan, principal scientist at AstraZeneca, and Andreas Plückthun, professor and head of biochemistry at the

Episode: 69 - Conversation with Sir Greg Winter on the 50th Anniversary of the Milstein and Köhler Paper

February 21, 2025 | This episode marks the 50th anniversary of one of the most influential papers in biomedical science—the 1975 Milstein and Köhler paper on hybridoma te